BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:VK2735 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of VK2735\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07838740-178@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:VK2735: Phase 1 readout est. (NCT07838740)
DESCRIPTION:VK2735\, phase 1\, Obesity.\nStudy: A Phase 1 Study of VK2735 i
 n Obese Adults Without Comorbidities\nEstimated primary completion: May 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/vk2735#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07838740
URL:https://assetmemo.bio/drug/vk2735#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07104500-178@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:VK2735: Phase 3 readout est. (NCT07104500)
DESCRIPTION:VK2735\, phase 3\, Obesity.\nStudy: VK2735 for Weight Managemen
 t Phase 3\nEstimated primary completion: 1 July 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/vk2735#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07104500
URL:https://assetmemo.bio/drug/vk2735#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07104383-178@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:VK2735: Phase 3 readout est. (NCT07104383)
DESCRIPTION:VK2735\, phase 3\, Obesity.\nStudy: VK2735 for Weight Managemen
 t Type 2 Diabetes Phase 3 (VANQUISH 2)\nEstimated primary completion: 1 Ju
 ly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/vk2735#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07104383
URL:https://assetmemo.bio/drug/vk2735#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07868835-178@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:VK2735: Phase 3 readout est. (NCT07868835)
DESCRIPTION:VK2735\, phase 3\, Obesity.\nStudy: Oral VK2735 for Weight Mana
 gement Phase 3 (SUNRISE 1)\nEstimated primary completion: July 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/vk2735#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07868835
URL:https://assetmemo.bio/drug/vk2735#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07868939-178@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:VK2735: Phase 3 readout est. (NCT07868939)
DESCRIPTION:VK2735\, phase 3\, Obesity.\nStudy: Oral VK2735 for Weight Mana
 gement in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)\nEstima
 ted primary completion: October 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/vk2735#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07868939
URL:https://assetmemo.bio/drug/vk2735#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
